Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
or

Tarsus Pharmaceuticals Inc (TARS)

Tarsus Pharmaceuticals Inc (TARS)
43.83 -2.04 (-4.45%) 15:14 ET [NASDAQ]
43.51 x 23 44.02 x 3
Realtime by (Cboe BZX)
43.51 x 23 44.02 x 3
Realtime 45.00 -0.87 (-1.90%) 08:00 ET
Quote Overview for Thu, Apr 10th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
41.78
Day High
44.87
Open 44.53
Previous Close 45.87 45.87
Volume 377,251 377,251
Avg Vol 712,042 712,042
Stochastic %K 31.08% 31.08%
Weighted Alpha +22.39 +22.39
5-Day Change -4.96 (-10.01%) -4.96 (-10.01%)
52-Week Range 20.08 - 57.28 20.08 - 57.28
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,760,353
  • Shares Outstanding, K 38,377
  • Annual Sales, $ 182,950 K
  • Annual Income, $ -115,550 K
  • EBIT $ -121 M
  • EBITDA $ -123 M
  • 60-Month Beta 0.94
  • Price/Sales 9.36
  • Price/Cash Flow N/A
  • Price/Book 7.60

Options Overview Details

View History
  • Implied Volatility 66.92% ( -1.89%)
  • Historical Volatility 56.83%
  • IV Percentile 18%
  • IV Rank 26.15%
  • IV High 127.03% on 11/08/24
  • IV Low 45.63% on 05/24/24
  • Put/Call Vol Ratio 0.47
  • Today's Volume 22
  • Volume Avg (30-Day) 32
  • Put/Call OI Ratio 0.32
  • Today's Open Interest 981
  • Open Int (30-Day) 1,138

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -0.75
  • Number of Estimates 5
  • High Estimate -0.65
  • Low Estimate -0.82
  • Prior Year -1.01
  • Growth Rate Est. (year over year) +25.74%

Price Performance

See More
Period Period Low Period High Performance
1-Month
40.38 +10.43%
on 04/09/25
Period Open: 44.59
52.63 -15.28%
on 03/24/25
unch (unch)
since 03/10/25
3-Month
40.38 +10.43%
on 04/09/25
Period Open: 52.69
57.28 -22.15%
on 02/05/25
-8.10 (-15.37%)
since 01/10/25
52-Week
20.08 +122.04%
on 08/05/24
Period Open: 35.88
57.28 -22.15%
on 02/05/25
+8.71 (+24.28%)
since 04/10/24

Most Recent Stories

More News
Tarsus Announces Pricing of Upsized $125.0 Million Public Offering

TARS : 43.83 (-4.45%)
Tarsus Announces Proposed $100.0 Million Public Offering

TARS : 43.83 (-4.45%)
Tarsus to Participate in Upcoming Investor Conference

TARS : 43.83 (-4.45%)
Tarsus Reports Strong Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Achievements

TARS : 43.83 (-4.45%)
Tarsus to Report Fourth Quarter and Full-Year 2024 Financial Results on Tuesday, February 25, 2025

TARS : 43.83 (-4.45%)
Tarsus to Participate in Upcoming Investor Conferences

TARS : 43.83 (-4.45%)
Tarsus Provides 2025 Update: Accelerating the Launch of XDEMVY® and Establishing Ocular Rosacea as the Next Category-Creating Opportunity in Eye Care

TARS : 43.83 (-4.45%)
The Zacks Analyst Blog Highlights ADMA Biologics, Tarsus Pharmaceuticals, Stoke Therapeutics, Inc. and ChromaDex

For Immediate ReleaseChicago, IL – December 26, 2024 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and...

CDXC : 7.87 (-0.88%)
ADMA : 18.71 (-3.51%)
TARS : 43.83 (-4.45%)
STOK : 6.28 (-2.33%)
4 Drug, Biotech Stocks Rising More Than 50% in 2024 With Room to Grow

The biotech sector witnessed a see-saw performance in 2024. While the year started on a positive note, much of the gains slowed down in the second half of 2024. The downside in the second half was due...

CDXC : 7.87 (-0.88%)
ADMA : 18.71 (-3.51%)
TARS : 43.83 (-4.45%)
STOK : 6.28 (-2.33%)
Tarsus Reports Third Quarter and Year-to-Date 2024 Financial Results and Recent Business Achievements

TARS : 43.83 (-4.45%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Sell with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

Tarsus Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It is focused on the development and commercialization of therapeutic candidates to address ophthalmic conditions. The company's product candidate consist TP-03 which is in clinical stage. Tarsus Pharmaceuticals Inc. is based...

See More

Key Turning Points

3rd Resistance Point 53.92
2nd Resistance Point 50.12
1st Resistance Point 47.99
Last Price 43.83
1st Support Level 42.06
2nd Support Level 38.26
3rd Support Level 36.13

See More

52-Week High 57.28
Last Price 43.83
Fibonacci 61.8% 43.07
Fibonacci 50% 38.68
Fibonacci 38.2% 34.29
52-Week Low 20.08

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar